The Target Differences of Anti-Tumorigenesis Potential of Curcumin and its Analogues Against HER-2 Positive and Triple-Negative Breast Cancer Cells

Edy Meiyanto ^1,2 * , Ulfatul Husnaa ¹, Ria Fajarwati Kastian ¹ , Herwandhani Putri ¹, Yonika Arum Larasati ¹ , Annisa Khumaira ¹, Dyaningtyas Dewi Putri Pamungkas ^1,3, Riris Istighfari Jenie ^1,2 , Masashi Kawaichi ^4,5, Beni Lestari ¹ , Takashi Yokoyama ⁶, Jun-ya Kato ⁶

Cited by CrossRef: 12

1- Flint A, Hansen D, Brown L, Stewart L, Ortiz E, Panda S. Modified Curcumins as Potential Drug Candidates for Breast Cancer: An Overview. Molecules. 2022;27(24):8891 [Crossref]

2- Hasbiyani N, Wulandari F, Nugroho E, Hermawan A, Meiyanto E. Bioinformatics Analysis Confirms the Target Protein Underlying Mitotic Catastrophe of 4T1 Cells under Combinatorial Treatment of PGV-1 and Galangin. Sci Pharm. 2021;89(3):38 [Crossref]

3- Bai H, Wang R, Li Y, Liang X, Zhang J, Sun N, Yang J, Tennekoon K. Network Pharmacology Analysis, Molecular Docking, and In Vitro Verification Reveal the Action Mechanism of Prunella vulgaris L. in Treating Breast Cancer. Evidence-Based Complementary and Alternative Medicine. 2022;2022:1 [Crossref]

4- Hermawan A, Putri H. Systematic analysis of potential targets of the curcumin analog pentagamavunon-1 (PGV-1) in overcoming resistance of glioblastoma cells to bevacizumab. Saudi Pharmaceutical Journal. 2021;29(11):1289 [Crossref]

5- Novitasari D, Nakamae I, Istighfari Jenie R, Yoneda-Kato N, Kato J, Meiyanto E. Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies. Saudi Pharmaceutical Journal. 2024;32(1):101892 [Crossref]

6- Nugraheni N, Zulfin U, Lestari B, Hapsari N, Ikawati M, Utomo R, Suenaga Y, Hippo Y, Meiyanto E. PGV-1 Causes Disarrangement of Spindle Microtubule Organization Resulting in Aberrant Mitosis in HLF and HuH6 Cells Associated with Altered MYCN Status. Adv Pharm Bull. 2024;14(3):665 [Crossref]

7- Novitasari D, Jenie R, Wulandari F, Utomo R, Pamungkas Putri D, Kato J, Meiyanto E. Curcumin-like structure (CCA-1.1) induces permanent mitotic arrest (Senescence) on Triple-negative breast cancer (TNBC) cells, 4T1. RJPT. 2021;:4375 [Crossref]

8- Wulandari F, Ikawati M, Widyarini S, Kirihata M, Novitasari D, Kato J, Meiyanto E. Tumour‐suppressive effects of curcumin analogs CCA‐1.1 and Pentagamavunone‐1 in colon cancer: In viv o and in vitro studies. 2023;14(4):317 [Crossref]

9- Yin Y, Tan Y, Wei X, Li X, Chen H, Yang Z, Tang G, Yao X, Mi P, Zheng X. Recent Advances of Curcumin Derivatives in Breast Cancer. Chemistry & Biodiversity. 2022;19(10) [Crossref]

10- Utomo R, Wulandari F, Novitasari D, Lestari B, Susidarti R, Jenie R, Kato J, Sardjiman S, Meiyanto E. Preparation and Cytotoxic Evaluation of PGV-1 Derivative, CCA-1.1, as a New Curcumin Analog with Improved-Physicochemical and Pharmacological Properties. Adv Pharm Bull. 2022;12(3):603 [Crossref]

11- Kannan M, Thilagavathi R, Selvam C. Antioxidant, anticancer, and toxicological evaluation of semi-synthetic curcumin benzothiazole analogue. Toxicol Environ Health Sci. 2023;15(1):85 [Crossref]

12- Amalina N, Salsabila I, Zulfin U, Jenie R, Meiyanto E. In vitro synergistic effect of hesperidin and doxorubicin downregulates epithelial-mesenchymal transition in highly metastatic breast cancer cells. J Egypt Natl Canc Inst. 2023;35(1) [Crossref]

13- Endah E, Wulandari F, Putri Y, Jenie R, Meiyanto E. Piperine Increases Pentagamavunon-1 Anti-cancer Activity on 4T1 Breast Cancer Through Mitotic Catastrophe Mechanism and Senescence with Sharing Targeting on Mitotic Regulatory Proteins. Iran J Pharm Res. 2022;21(1) [Crossref]